Current therapy for acute myeloid leukaemia (AML) is suboptimal with a high incidence of relapse. There is strong evidence that constitutive phosphoinositide 3-kinase (PI3K) activity plays a significant role in the pathophysiology of AML. PI3K products are derived from the activity of a number of PI3K catalytic isoforms (class I, II and III) but the relative contribution of these enzymes in AML remains unknown. As non-isoformselective inhibitors of PI3K such as LY294002 may produce unwanted toxicity to normal tissues, we have investigated the role of the leukocyte-restricted p110d PI3K isoform in 14 cases of AML. p110d was detected in all cases whereas the expression levels of the other class I PI3Ks varied more widely, and were often undetectable. The p110d-selective compound IC87114 inhibited constitutive phosphorylation of the PI3K target Akt/PKB and reduced cell number to a mean of 6675% (range 14-88%). In eight cases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing viable cell number, and was associated with a reduction in constitutive NF-jB activity. IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal haemopoietic progenitors. Overall, our results identify the p110d isoform as a potential therapeutic target in AML and support a clinical approach to use isoform-selective over broad-spectrum PI3K inhibitors.
Introduction
Acute myeloid leukaemia (AML) is a clonal haematological disease characterized by a myriad of genetic abnormalities leading to alterations in signal transduction pathways and transcription factor regulation that induce excessive proliferation and impair cell differentiation (Kelly and Gilliland, 2002; Warner et al., 2004) . There is now increasing evidence for the contribution of constitutive phosphoinositide 3-kinase (PI3K) activity in the molecular pathogenesis of AML. Several groups, including our own, have shown that the protein kinase Akt/PKB, a major downstream target of PI3K, is phosphorylated and activated in the majority of primary AML cells and that constitutive activation of the PI3K/ Akt pathway is necessary for both the sustained proliferation (Kubota et al., 2004) and the survival of AML cells (Xu et al., 2003; Grandage et al., 2005) . In addition, constitutive activation of Akt/PKB may be associated with poor prognosis of AML, and contribute to chemoresistance (Min et al., 2003) .
PI3Ks are important regulators of intracellular signal transduction pathways mediating cell proliferation, differentiation, survival and migration of various cell types, including haematological cells (Okkenhaug and Vanhaesebroeck, 2003; Okkenhaug et al., 2004) . Mammals have eight PI3K isoforms that can be divided into three distinct classes (class I, II and III) (Vanhaesebroeck et al., 1997a; Vanhaesebroeck and Waterfield, 1999) . Class I PI3K enzymes produce the PIP3 lipid, that is critical for the activation of Akt/PKB. Other classes of PI3K are not known to significantly contribute to the synthesis of this key lipid. Class I PI3K catalytic subunits are subdivided into class IA and IB, depending on the nature of their regulatory subunits. The class IA PI3Ks signal downstream of tyrosine kinases and Ras, and are heterodimers consisting of a 110 kDa catalytic subunit (commonly known as p110), which couples to a regulatory subunit of which there are at least five isoforms (p85a, p85b, p55g, p55a and p50a). The regulatory subunits have SH2 domains that bind specific phosphotyrosine residues of activated growth factor receptors or adaptor proteins, inducing a translocation of the cytosolic PI3Ks to the membrane where their lipid substrates reside (Cantley, 2002) . The Class IA subset of PI3Ks comprises the catalytic isoforms p110a, p110b and p110d, whereas p110g is the single class IB PI3K catalytic subunit. Earlier work assessing tissue distribution of Class IA PI3K isoforms has established that p110a and p110b are widely expressed, whereas p110d is highly enriched in leucocytes (Chantry et al., 1997; Vanhaesebroeck et al., 1997b) .
The PI3K/Akt pathway is involved in the pathogenesis of several human diseases including cancer and inflammatory disorders (Vivanco and Sawyers, 2002; Luo et al., 2003a; Wymann et al., 2003) . Enhanced PI3K activity in cancer can be the result of oncogenic activation of upstream regulators of PI3K (such as tyrosine kinases and Ras), PI3K gene amplification and/ or mutation, especially of the p110a subunit (Shayesteh et al., 1999; Vivanco and Sawyers, 2002; Fresno Vara et al., 2004; .
Efforts are underway to define the role(s) of individual PI3K isoforms in normal and pathophysiological processes, with increasing evidence for a nonredundant function of the class I PI3K p110 enzymes (Roche et al., 1994; Hill et al., 2000; Okkenhaug et al., 2002; Sawyer et al., 2003; Ali et al., 2004; Fruman, 2004) . These findings, amongst others, form the basis for the ongoing development in the pharmaceutical industry of isoform-selective PI3K inhibitors (Robertson et al., 2001; Sadhu et al., 2001 Sadhu et al., , 2003 Hayakaa et al., 2002; Camps et al., 2005; Jackson et al., 2005) . There is strong evidence for cancer-specific p110a mutations Kang et al., 2005) and the development of selective p110a inhibitors is in progress (Robertson et al., 2001; Hayakaa et al., 2002) . Recently, Jackson et al. (2005) showed that p110b plays a key role in platelet activation, highlighting the potential use of p110b-selective inhibitors as antithrombotic agents. The PI3K isoforms p110d and p110g play essential roles in immunity, and are important new targets in inflammation and autoimmunity (Wymann et al., 2003) .
Here, we have investigated the contribution of the p110d isoform of PI3K in regulating cell proliferation and survival in primary AML cells and in the AMLderived cell line THP-1. In these studies, we used LY294002, a broad spectrum PI3K inhibitor, and IC87114, a newly described compound that selectively inhibits the activity of the class I PI3K p110d isoform (Sadhu et al., 2001 (Sadhu et al., , 2003 Sawyer et al., 2003; Ali et al., 2004; Bilancio et al., 2005) . We have also examined if IC87114 enhances the cytotoxic effect of the chemotherapeutic agent VP16 on AML cells and identified downstream targets and molecular mechanisms by which this may occur. Table 1 shows the clinical details of the 14 cases of AML that were investigated in this study. The expression levels of class I PI3K isoforms in AML cells were analysed by immunoblotting of total cell lysates using antibodies specific for the p85 regulatory subunit or the p110a, p110b, p110d and p110g catalytic subunits. Whereas p85 was present in all primary AML samples ( Figure 1, left panel) , expression of the p110 catalytic subunits was highly variable. Interestingly, p110d was found in all primary AML samples in contrast to the other p110 catalytic subunits, which in some cases were expressed at a low level or could not be detected (Figure 1, left panel) . In three out of 12 cases (cases 1, 2 and 3), p110d was the only class I PI3K detected. In purified normal CD34 þ progenitor cells, p85 and p110d are also easily detectable, while expression of the other p110 subunits was either low (p110a) or undetectable (p110b) (Figure 1 , right panel and data not shown). In contrast, all class I PI3K subunits were detected in the THP-1 AML cell line (Figure 1, right panel) . Taken together, these results indicate that of all four class I PI3K catalytic subunits, p110d is the predominant isoform in primary AML cells, the THP-1 cell line and normal CD34 þ progenitor cells.
Results

Class I PI3K isoform expression in AML cells
Constitutive activation of PI3K in AML cells
To determine the PI3K activation status in primary AML, we analysed the phosphorylation of the PI3K target Akt/PKB by immunoblotting using phosphospecific antibodies for threonine 308 (T308) or serine 473 (S473), two sites that require phosphorylation for full activation of this kinase (Bayascas and Alessi, 2005) . In keeping with previously reported results, we found constitutive phosphorylation of Akt/PKB in primary AML cells and in the AML cell line THP-1 (Figure 2 ). This contrasts with normal CD34 þ progenitors in which Akt/PKB phosphorylation is only detectable in response to added growth factors (Grandage et al., 2005) . The Forkhead-related transcription factor 1 (Foxo3a, previously referred to as FKHR-L1) is a known substrate for Akt/PKB (Dijkers et al., 2000b) and was frequently found to be constitutively phosphorylated in primary AML cells (Figure 2 ). For both primary AML ( Figure  2a and b) and THP-1 cells (Figure 2b) , a 4 h incubation with the broad spectrum PI3K inhibitor LY294002 (20 mM) led to a substantial dephosphorylation of Akt/ PKB and Foxo3a. Incubation of AML cells with the p110d-selective inhibitor IC87114 also reduced the constitutive phosphorylation of Akt/PKB ( Figure 2 ) but with variable effect. In some cases, the reduction in phosphorylation was similar to that seen with LY294002 (cases 1, 4, 5 and 11) but in the majority the reduction was partial. In keeping with the effects of IC87114 on Akt/PKB phosphorylation, we also found a reduction in phosphorylation of Foxo3a (Figure 2 ). The proapoptotic protein Bim is one of the transcriptional targets of Foxo3a (Dijkers et al., 2000a) . However, no correlation between the level of Bim and Foxo3a activation either before or after treatment with PI3K inhibitors was observed (Figure 2a Constitutive Akt/PKB phosphorylation may be due to downregulation of expression or function of the phosphatase and tensin homolog (PTEN) lipid phosphatase, one of the key negative regulators of class I PI3K function. We found that PTEN protein is expressed at a similar level in all primary AML samples, the THP-1 cell line and normal CD34 þ progenitor cells (Figure 2c ), consistent with our previous observations (Grandage et al., 2005) . Given that PTEN mutations are reported to be very infrequent and/or absent in AML (Aggerholm et al., 2000) , we did not screen for these in this study. PTEN has also been reported to be phosphorylated at the C-terminus in AML, a process which may lead to a reduction in its activity. (Vazquez et al., 2000; Cheong et al., 2003) . We found that only 2 of 11 AML cases examined showed weak PTEN phosphorylation as measured with an antibody against phospho-S380/T382/T383 (data not shown). Taken together, these data suggest that dysregulation of the PTEN protein does not make a major contribution to Abbreviations: BMT, bone marrow transplant; CR, complete remission; ITD, internal tandem duplication; TKD, tyrosine kinase domain mutation; TRM, treatment-related mortality; WCC, white cell count; WT, wild type. Mutation analysis were carried out according to methods described in Grandage et al. (2005) . Day, week or month correspond to the time from diagnosis when patient died or to the time from diagnosis until last reviewed when patient is alive. β -actin
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Effects of IC87114 on primary AML cell survival and proliferation
We next assessed the effect of IC87114 on AML cell proliferation and survival. Primary AML cells were incubated with varying doses of IC87114 (up to 5 mM) followed by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay 72 h later ( Figure 3a , upper panel). These are concentrations at which this compound is highly selective for p110d in cells (Sadhu et al., 2003) and does not affect cells in which p110d is genetically inactivated (Ali et al., 2004; Bilancio et al., 2005) . We found variable sensitivity of primary AML samples to 5 mM IC87114 with MTS activity being reduced to an average of 6675% of control (range 14-88%) ( Figure 3a , lower panel). Clonogenic assays in methylcellulose were carried out using cells from two AML patients and showed results consistent with those found in liquid culture ( Figure 3b ). THP-1 cells show constitutive activation of PI3K and a 2.5 mM dose of IC87114 reduced proliferation and survival to 8175% ( Figure 4a , left panel), and 8472% of control ( Figure 4a , middle panel), respectively, and had a similar effect on colony formation ( Figure 4a , right panel). In parallel incubations, the impact of LY294002 on primary AML and THP-1 cells was higher than that of IC87114 (Figures 3 and 4a ). This could be due to the more profound reduction in PI3K activity achieved with LY294002 in most cases (as evidenced by a stronger reduction in Akt/PKB phosphorylation) but may also be due to non-PI3K off-target effects of this compound. Indeed, apart from PI3Ks, LY294002 also inhibits a broad variety of non-PI3K enzymes such as Casein Kinase-2, Pim kinase, DNA-PK, polo-like kinases and mTOR (Knight et al., 2004) . LY294002, in contrast to IC87114, also reduced proliferation and induced apoptosis in normal progenitors with a marked reduction of colony number (Figure 4b ) and colony size (data not shown).
IC87114 can enhance the cytotoxic effect of VP16 in primary AML cells PI3K/Akt signalling contributes to primary AML cell survival and its constitutive activation can reduce the effectiveness of cytotoxic agents (Xu et al., 2003; Zhao et al., 2004) . Primary AML cells were incubated with IC87114 (1-5 mM) together with a low dose of VP16 (0.5 mM), a proapoptotic drug widely used in chemotherapy of AML, followed by MTS assay 72 h later. The AML cases studied here fell into two distinct subgroups. In the first one, consisting of six samples (shown individually in Figure 5a (left upper panel) and summarized in Figure 5b (left panel)), IC87114 alone caused a marked reduction in AML cell survival to a mean of 6575%. Addition of VP16 did not alter this significantly (mean cell survival of 5676%; cell survival upon treatment with VP16 alone was 9573%; Figure 5b ). Thus, in this first subgroup the impact of the combination IC87114 and VP16 was additive. In the second subgroup, which included eight patients (shown individually in Figure 5a (right upper panel) and summarized in Figure 5b (right panel), IC87114 on its own caused a modest reduction in AML cell survival (cell survival reduced to a mean of 8877%; Figure 5b ) but combination with VP16 led to a synergistic response (cell survival reduced to 4675%; cell survival of VP16 on its own was 9275%; Figure 5b ). These results show that inhibition of Role of p110d PI3K in AML cell survival and chemoresistance C Billottet et al p110d activity can potentiate the response to VP16 in a significant proportion of primary AML cells. In addition, imunoblotting of total cell lysate from primary AML cells treated with or without VP16 show that VP16 does not affect the phosphorylation of Akt/PKB, suggesting that VP16 has no impact on PI3K/Akt signaling ( Figure 5c ). We evaluated if the expression pattern of p110 isoforms or the reduction in Akt/PKB phosphorylation induced by IC87114 could predict the type of cytotoxic response seen. Figure 5a (the two lower panels) shows that cases AML 1, 2 and 3, which express only the p110d isoform all belong to subgroup II (weak sensitivity to IC87114 on its own, synergy between IC87114 and VP16). However, other patterns of p110 isoform expression did not correlate with the type of response to IC87114. In those cases where there was sufficient material for analysis, there was no correlation between the reduction in Akt/PKB phosphorylation observed with IC87114 and cytotoxic response (Figure 2) .
Our results also show that the combination of IC87114 and VP16 is moderately synergistic in THP-1 cells (Figure 6a ). In these cells, IC87114 was able to effectively inhibit Akt/PKB phosphorylation with or without VP16, suggesting again that VP16 has no impact on this pathway in AML cells (Figure 6b , right panel). The effect of the combination of IC87114 and VP16 on the survival of purified normal CD34 þ progenitor cells was also investigated. The addition of VP16 induced a dose-dependent reduction in survival in normal progenitors but this was unaffected by coincubation with IC87114 (Figure 6c ). This indicates that, in contrast to the results with AML cells, inhibition of the p110d PI3K isoform does not enhance the cytotoxic effects of VP16 on normal progenitors.
The combination of IC87114 with VP16 increases apoptosis and inhibits NF-kB activity in AML cells To determine whether inhibition of p110d regulates cell survival, we measured the levels of apoptosis upon incubation with IC87114 with or without VP16, using a flow cytometric assay of Annexin V binding. 24 h incubation in the presence of 5 mM IC87114 resulted in a 2177% increase in Annexin V-positive cells in primary AML cells (Figure 7a ). This suggests that the reduction in cell number observed with 5 mM of IC87114 using the 72 h MTS assay was at least partly due to increased apoptosis.
It has been reported that the NF-kB survival pathway is constitutively activated in AML (Guzman et al., 2001) and may be positively regulated by PI3K/Akt (Grandage et al., 2005) . We therefore investigated, using an NF-kB-responsive reporter gene assay, the contribution of the PI3K/p110d pathway in regulating the constitutive activation of NF-kB in primary AML cells. In the six AML cases investigated for NF-kB activity, we found constitutive activation of the reporter construct. For the AML case 9 (Figure 7b , top panel), both IC87114 and VP16 on their own reduced basal NF-kB activity significantly while for the five other cases this basal activity was only slightly reduced by IC87114 on its own (Figure 7b, top panel) . Interestingly, although in those latter cases where total reporter activity was not decreased in the presence of VP16, coincubation of VP16 with IC87114 in four cases (1, 2, 5 and 6) suppressed NF-kB activity to a mean of 6579% (Figure 7b, bottom panel) . All four of these cases were from the subgroup of patients who showed a synergistic effect of the combination IC87114/VP16 in decreasing cell survival (Figure 6a Role of p110d PI3K in AML cell survival and chemoresistance C Billottet et al VP16 may be mediated by inhibition of the NF-kB pathway.
Discussion
AML remains a clinical challenge with poor long-term survival and the identification of aberrantly activated signaling pathways provides an opportunity to improve the standard chemotherapeutic treatments. The clinical concept of PI3K blockade as a targeted therapy is clearly attractive with the recognition that the PI3K/Akt transduction pathway plays an important role in regulating cancer cell growth, survival, motility and invasion (Brognard et al., 2001; Nicholson and Anderson, 2002; Luo et al., 2003a; Fresno Vara et al., 2004) . There is now increasing evidence for its role in the Role of p110d PI3K in AML cell survival and chemoresistance C Billottet et al regulation of AML cell cycle progression and survival and therefore for its contribution to the malignant phenotype of AML cells (Xu et al., 2003; Kubota et al., 2004; Grandage et al., 2005) . Class IA PI3Ks are the most studied isoforms of PI3K, given that this subgroup of PI3Ks produces the PIP3 lipid that activates Akt/ PKB downstream of tyrosine kinases (e.g. Flt3, c-kit) and Ras, which are often mutated in AML (Neubauer et al., 1994; Stirewalt and Radich, 2003) . In addition, class IA PI3K isoforms have been shown to have specialized signaling functions in haematopoietic cells (Vanhaesebroeck et al., 1997b; Vanhaesebroeck and Waterfield, 1999; Okkenhaug et al., 2002; Okkenhaug and Vanhaesebroeck, 2003; Reif et al., 2004) and to have the desired molecular characteristics that make them excellent targets for small molecule inhibitors In this study, we show that both primary AML and the established THP-1 myeloid cell line have constitutive PI3K activity as characterized by the phosphorylation of the Akt/PKB protein kinase and its substrate Foxo3a. Interference within the PI3K pathway using the pan-PI3K inhibitor LY294002 suppresses the activation of PI3K/Akt/Foxo3a signaling pathway in all primary AML cells and in THP-1 cells. Our in vitro analyses were The combination of IC87114 and VP16 increases apoptosis and inhibits NF-kB activity in patient AML cells. (a) Annexin V assay was used to detect the % of apoptotic cells in primary AML cells (number of AML cases ¼ 7) treated overnight with IC87114, VP16 or in combination. (b) A cis reporter assay was used to measure the NF-kB activity in primary AML cells treated overnight with IC87114, VP16 or in combination. Bottom panel, the average of the NF-kB activity was quantitated from the four AML patients that belong to the subgroup with synergistic response to the combination IC87114/VP16 (AML 1, 2, 5 and 6).
Role of p110d PI3K in AML cell survival and chemoresistance C Billottet et al performed in the absence of exogenously added cytokines, and at present, the mechanism of constitutive activation of PI3K/Akt/Foxo3a in these cells remains unclear. Constitutive activation of the PI3K pathway in many tumour types is known to result from inactivation of PTEN, a lipid phosphatase, which degrades PIP3 and thus antagonizes the PI3K/Akt axis. PTEN is a tumour suppressor and the loss of its activity (through loss of function and/or loss of expression) is known to lead to increased PI3K signaling (Simpson and Parsons, 2001; Parsons, 2004) . In agreement with previous studies, we found that PTEN protein expression was readily detected in all our AML samples. PTEN may also be regulated by C-terminal phosphorylation and it has been suggested that this correlates with increased activity of Akt/PKB in AML . Weak PTEN phosphorylation on these S380/T382/T383 sites was found in only two of 11 cases in our study (data not shown) indicating that this is unlikely to be a major mechanism leading to constitutive Akt/PKB activation. The SH2 domain-containing 5 0 -phosphatase (SHIP) is also a negative regulator of PIP3 levels and a possible role of the mutation of the SHIP gene in the development of acute leukaemia has been suggested (Luo et al., 2003b) , indicating that further studies of gene mutation in this lipid phosphatase are warranted.
Abnormalities in signalling pathways upstream of PI3K could also lead to constitutive PI3K activity, for example, as a consequence of somatic mutations in haematopoietic tyrosine kinases and Ras which are known to confer proliferative and/or survival advantage to AML cells (Neubauer et al., 1994; Kelly and Gilliland, 2002; Stirewalt and Radich, 2003; Nanri et al., 2005) . We did not find a correlation between the mutational status of N-Ras and Flt3 and the level of activation of PI3K/Akt/Foxo3a pathway in the AML cases in our study (Table 1) . It is possible that other mechanisms such as autocrine growth factor production contribute to the activation of PI3K in AML cells. Further studies into the mechanisms by which PI3K is activated in these cells are therefore required.
AML cells require PI3K for proliferation and survival as shown by the effect of the pan-PI3K inhibitor LY294002 (Xu et al., 2003; Kubota et al., 2004; Zhao et al., 2004; Grandage et al., 2005; Sujobert et al., 2005) . However, the toxicity of such a broad spectrum inhibitor is likely to preclude its use from the clinic. In fact, we show that LY294002 markedly inhibits the proliferation and survival of normal CD34 þ progenitor cells suggesting that LY294002 (or similar compounds) may induce unacceptable toxic side effects in vivo. Such a negative impact from targeting the PI3K pathway may be overcome by the use of inhibitors with selectivity for one or more class I PI3Ks. Given that only the p110d isoform was detected in all cases of AML, together with the fact that this PI3K isoform is largely restricted to leucocytes (Chantry et al., 1997; Vanhaesebroeck et al., 1997b) suggests that p110d could be a good target in this leukaemia. p110d activity is also not required for organismal development and integrity (Clayton et al., 2002; Jou et al., 2002; Okkenhaug et al., 2002) , indicating that the blockade of p110d may be less toxic compared to one of the other class IA p110 isoforms. IC87114 is a newly described compound that selectively inhibits the activity of p110d (Sadhu et al., 2003; Sawyer et al., 2003; Ali et al., 2004; Bilancio et al., 2005; Sujobert et al., 2005) . Our study shows that in AML cells the effect of IC87114 at optimal concentrations was variable, but reduced cell number to a mean of 6675% of control. In the majority of cases, the reduction in phosphorylated Akt/PKB and Foxo3a proteins was partial with a variable inhibitory effect on AML cell proliferation and a modest increase in apoptosis. For four AML cases (cases 1, 4, 5 and 11) the reduction in PI3K/Akt/Foxo3a activation was as marked as that seen with LY294002 and 5 mM of IC87114 decreased cell number between 58-83% of control. The difference in efficacy of LY294002 and IC87114 in AML cell survival implicates PI3Ks other than p110d, or non-PI3K targets of LY294002 such as Casein Kinase 2, mTOR, DNA-PK, Pim1 and polo-like kinases (Knight et al., 2004) . Importantly, IC87114 did not inhibit cell proliferation and survival of normal CD34 þ progenitor cells suggesting that in vivo IC87114 may have limited toxicity on normal haemopoiesis. Sujobert et al. (2005) have also reported that p110d was the predominant isoform expressed in AML and that the proliferation of normal CD34 þ progenitor cells was not decreased by IC87114. However, they showed that IC87114 was as efficient as LY294002 at suppressing the phosphorylation of Akt/ PKB and at inhibiting cell proliferation in all AML samples investigated. This discrepancy could be related to technical differences between our studies. For example, Sujobert et al. (2005) used IC87114 at a higher concentration (10 mM) than in our study. Moreover, they also incubated primary AML cells in serum-free medium for 4 h before incubation with LY294002 or IC87114. Such a starvation step may sensitize AML cells to the treatment with various inhibitors. In addition, Sujobert et al. (2005) H]Thymidine may measure the impact of treatment on only a fraction of the cells. In contrast, the MTS assay, used in our study, better assesses the impact of treatment on the entire cell population (Kaspers and Veerman, 2003; Sargent, 2003) . However, both studies show that p110d is a potential target for therapeutic intervention in AML.
Current therapies to treat AML are frequently impeded by the development of resistance, which can occur at the onset of treatment or later after initial sensitivity. The topoisomerase II inhibitor VP16 is widely used for its antineoplastic activity in AML (Hande, 1998) . Consistent with the notion that PI3Ks have been implicated in chemoresistance (as determined using pan-PI3K inhibitors wortmannin and LY294002 (West et al., 2002) ), combination of IC87114 with low doses of VP16 showed a greater effect than treatment with each agent alone, both at the level of decreasing cell survival and inducing apoptosis. For eight of the AML cases, this combination had a synergistic cytotoxic effect. It is of interest that targeting a single isoform of PI3K, in this case p110d, has the capacity to potentiate the effect of chemotherapeutic agents. This synergistic effect was attributable in part to the enhancement of apoptosis, and may be related to inhibition of the NFkB pathway, which has been implicated in regulating the survival of AML cells (Grandage et al., 2005) . For four AML patients of this subgroup, the combination of IC87114 and VP16 synergistically reduced NF-kB activity with little or no additional effect on Akt/PKB activity. It is therefore possible that this combined treatment modulates other PI3K/p110d-dependent and/ or -independent effectors which lead to a reduction in NF-kB activity. It has been reported recently that the mTOR inhibitor rapamycin may exert a proapoptotic activity via inhibition of the NF-kB pathway through mechanisms independent of PI3K/Akt/mTOR in childhood acute lymphoblastic leukaemia (Avellino et al., 2005) . The significant differences in sensitivity to IC87114 on its own or in combination with VP16 observed among the various AML cases could not be readily predicted by the presence of a specific p110 isoform expression pattern. Of note however, cases that expressed only p110d showed synergy between IC87114 and VP16 for cytotoxicity but the sample numbers involved are small and further work is required to confirm this observation. Somatic mutations in p110a and p110d are rare in AML, our unpublished data (Samuels and Velculescu, 2004; Bousquet et al., 2005; Cornillet-Lefebvre et al., 2005) and further studies of gene amplification in p110 isoforms are warranted. We have also shown that, in contrast to the findings in AML cells, inhibition of p110d does not significantly affect the proliferation and survival of normal haemopoietic progenitors and does not enhance the cytotoxic effects of VP16.
In summary, we have demonstrated that AML cells consistently express the p110d isoform of PI3K. Our data suggest that the p110d isoform is one of the major PI3Ks that regulates the frequent constitutive activation of the PI3K/Akt/Foxo3a signaling pathway in these cells, impacting on the proliferation, survival and chemoresistance of these cells. p110d is therefore a potential drug target in AML. We have also shown that, in contrast to total blockade of PI3K activity, selective p110d inhibition has little toxicity to normal haemopoietic CD34 þ progenitor cells. These results are encouraging for the broader strategy of using isoformselective PI3K inhibitors as clinical therapeutic agents in a wide range of human diseases and provide a rationale for the use of isoform-selective PI3K inhibitors in combination with cytotoxic agents, resulting in reduced overall toxicity and increased therapeutic efficacy.
Materials and methods
Reagents LY294002 (Calbiochem, Nottingham, UK) and IC87114 (Sadhu et al., 2003) were dissolved in dimethylsulphoxide (DMSO) as a 10 mM stock solutions and stored at À201C. Sources of other reagents are: VP16 (also known as etoposide; Medac, Hamburg, Germany), human granulocyte-macrophage colony-stimulating factor (GM-CSF) and human IL-3 (Sandoz Pharmaceuticals), polyclonal anti-pan p85 and antiThr 32 phospho-Foxo3a and monoclonal anti-Akt/PKB (Upstate Biotechnology, Hampshire, UK), polyclonal antiAkt/PKB, anti-Ser 473 phospho-Akt/PKB, anti-Thr 308 phospho-Akt/PKB, anti-PTEN and monoclonal anti-p27/ Kip1 antibodies (Cell Signaling Technology, Danvers, MA, USA), monoclonal antibodies against b-actin and a-tubulin (Sigma, La Jolla, CA, USA), monoclonal antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam, Cambridge, UK). Polyclonal anti-p110a and anti-p110g antibodies were gifts from Calle Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden) and Reinhard Wetzker (Institute of Molecular Cell Biology, Jena, Germany), respectively. Polyclonal antibodies to p110d have been described (Vanhaesebroeck et al., 1997b) and polyclonal anti-p110b antibodies were purchased from Santa-Cruz, Santa Cruz, CA, USA (sc-602).
Cell culture Samples were obtained from patients at University College Hospital, London, at presentation of AML and before treatment. Informed consent was obtained from all patients before obtaining the sample. All patients had circulating leukaemic blasts in the peripheral blood. Leukaemic blasts were isolated by Ficoll gradient centrifugation and mononuclear cells frozen in Roswell Park Memorial Institute media (RPMI) 1640 with 10% DMSO, 20% foetal calf serum (FCS) and L-glutamine (Invitrogen), and stored in liquid nitrogen. Of the samples analysed, 11/14 AML samples were from frozen stocks and the remainder were analysed fresh. THP-1, an established AML cell line (Odero et al., 2000) , was used as a control in our experiments. Fresh or frozen/thawed AML cells and THP-1 cells were cultured in RPMI culture medium supplemented with 10% FCS, L-glutamine, penicillin and streptomycin (this culture medium is further referred to as RPMI/10% FCS). No exogenous cytokines were added to the culture medium. CD34 þ progenitor cells were isolated and cultured according to the methods of Watts et al. (2002) .
Cell proliferation assays
Cells were seeded in 96-well plates containing three replicate wells per assay condition at a density of 1 Â 10 4 (THP-1) or 2 Â 10 5 (primary AML) cells/well in 0.1 ml of RPMI/10% FCS. Cells were cultured for 72 h at 371C in 5% CO 2 with the indicated concentrations of compounds. In all experiments where pharmacological inhibitors were used, an equivalent volume of DMSO carrier was added to the control cells. Relative cell survival was measured using the CellTiter96 aqueous nonradioactive cell proliferation kit (Promega, Southampton, UK), which is based on the MTS (a tetrazolium compound) colorimetric dye reduction that allows the determination of the number of viable cells. The MTS assay was carried out according to the manufacturer's instructions. Cell survival using normal CD34 þ progenitor cells were carried out using standard techniques (Watts et al., 2002) . DNA synthesis was measured by [ 3 H]Thymidine incorporation during the last 6 h of the 72 h culture period. Data were calculated relative to values obtained with cells cultured in DMSO alone. Results were quantitated from three independent experiments to calculate mean and s.e.
Colony assay THP-1 and primary AML cells were treated for 1 h with DMSO, 2.5 mM IC87114 or 20 mM LY2904002. Cells were then plated in semisolid Methocult Methylcellulose medium (StemCell Technologies, Vancouver, Canada), at a density of 200 THP-1 cells and 1000 primary AML cells per six-well plate in the presence of fresh inhibitor (inhibitors were added once at start of culture and not replenished). For primary AML cells Methocult Methylcellulose medium was further supplemented with 20 ng/ml of GM-CSF and 20 ng/ml of IL-3. Plates were incubated for 10 days (THP-1 cells) to 16 days (primary AML cells), and the number of colonies was counted in situ by light microscopy. For THP-1 cells, results were quantitated from three independent experiments to calculate mean and s.e. Colony assays using normal CD34 þ progenitor cell were carried out using standard techniques (Watts et al., 2002) .
Cell lysis and Western blot analysis
Cells were washed twice with phosphate-buffered saline (PBS) and dissolved in lysis buffer (50 mM Tris.HCl pH 7.4, 150 mM NaCl, 1 mM ethylenediamine-N, N, N 0 , N 0 -tetraacetic acid (EDTA), 1% (v/v) Triton X-100 supplemented with protease and phosphatase inhibitors). Protein concentration was quantified by Bio-Rad method (Hercules, CA, USA). Cell lysates were resuspended in sample buffer (62.5 mM Tris.HCl pH 6.8, 2% sodium dodecyl sulphate (SDS), 10% glycerol and 0.1% bromophenol blue, 1% b-mercaptoethanol), boiled for 5 min and resolved by SDS-PAGE. Proteins were electroblotted onto a polyvinylidene difluoride (PVDF) membrane membrane (Amersham). Membranes were probed with the indicated antibodies, followed by detection using donkey antirabbit IgG or sheep anti-mouse IgG (both conjugated to horseradish peroxidase; Amersham, Piscataway, NJ, USA) and enhanced chemiluminescence (Amersham). For reprobing, antibodies were stripped from the membranes by incubation for 45 min at 551C in 62.5 mM Tris.HCl pH 6.8, 2% SDS and 100 mM b-mercapthoethanol.
Apoptosis assay
The apoptosis assay based on annexin V cell surface binding was carried out according to the manufacturer's instructions (BD Biosciences). Primary AML cells (10 6 /ml) were incubated overnight in six-well plates with the indicated compounds, and then pelleted by centrifugation. Following two washes with PBS, cells were incubated with anti-annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI). Single-cell suspensions were analysed by FACScan. Apoptotic cells were scored as annexin V þ , PI À (annexin V þ , PI þ are considered to be necrotic cells).
Luciferase reporter assay
The Dual Luciferase Reporter Assay System (Promega) was used, in which the NF-kB luciferase reporter plasmid (pNFkB-Luc that contains tandem copies of the k enhancer element) and the renilla luciferase plasmid (pRL-cytomegalovirus (CMV) to standardize for transfection efficiency) are cotransfected. Primary AML cells 5 Â 10 6 were nucleofected (Amaxa kit V, Amaxa Biosystems, Germany) with 2 mg of pNF-kB-Luc and 0.2 mg of pRL-CMV, followed by overnight incubation in RPMI/10% FCS with the indicated compounds. Cells were then lysed and quantified for luciferase activity according to the manufacturer's instructions. NF-kB reporter activity was corrected for the renilla luciferase activity.
